• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.

作者信息

Dwojak M, Bobrowicz M, Bil J, Bojarczuk K, Pyrzynska B, Siernicka M, Malenda A, Lech-Maranda E, Tomczak W, Giannopoulos K, Golab J, Winiarska M

机构信息

1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Postgraduate School of Molecular Medicine, Warsaw, Poland.

1] Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland [2] Department of Invasive Cardiology, Central Clinical Hospital of the Ministry of Interior, Warsaw, Poland.

出版信息

Blood Cancer J. 2015 Apr 10;5(4):e300. doi: 10.1038/bcj.2015.27.

DOI:10.1038/bcj.2015.27
PMID:25860291
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4450327/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c95/4450327/a318bae09734/bcj201527f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c95/4450327/63da9f381123/bcj201527f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c95/4450327/a318bae09734/bcj201527f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c95/4450327/63da9f381123/bcj201527f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c95/4450327/a318bae09734/bcj201527f2.jpg

相似文献

1
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.索拉非尼通过降低补体调节蛋白的表达来提高利妥昔单抗和奥法木单抗的疗效。
Blood Cancer J. 2015 Apr 10;5(4):e300. doi: 10.1038/bcj.2015.27.
2
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.奥法妥木单抗在裂解全血中的 B 慢性淋巴细胞白血病细胞方面比利妥昔单抗更有效，并且与化疗联合使用时也是如此。
J Immunol. 2013 Jan 1;190(1):231-9. doi: 10.4049/jimmunol.1202645. Epub 2012 Dec 5.
3
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.抗CD20抗体（IDEC-C2B8，利妥昔单抗）在体外增强细胞毒性药物对肿瘤淋巴细胞的疗效：细胞因子、补体和半胱天冬酶的作用
Haematologica. 2002 Jan;87(1):33-43.
4
Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment.慢性淋巴细胞白血病：2015 年诊断、风险分层和治疗更新。
Am J Hematol. 2015 May;90(5):446-60. doi: 10.1002/ajh.23979.
5
Efficacy of ofatumumab against rituximab-resistant B-CLL/SLL cells with low CD20 protein expression.奥法木单抗对低CD20蛋白表达的利妥昔单抗耐药B细胞慢性淋巴细胞白血病/小淋巴细胞淋巴瘤细胞的疗效。
Br J Haematol. 2014 Aug;166(3):455-7. doi: 10.1111/bjh.12857. Epub 2014 Mar 27.
6
Combination therapy with ofatumumab and bendamustine in xenograft model of chronic lymphocytic leukaemia.奥法木单抗与苯达莫司汀联合治疗慢性淋巴细胞白血病异种移植模型。
Br J Haematol. 2012 Feb;156(3):402-4. doi: 10.1111/j.1365-2141.2011.08829.x. Epub 2011 Aug 18.
7
Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature.奥法木单抗治疗与慢性淋巴细胞白血病相关的利妥昔单抗难治性自身免疫性溶血性贫血：一例报告并文献复习
Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):511-3. doi: 10.1016/j.clml.2013.02.022. Epub 2013 May 29.
8
Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.p53 突变型和 ATM 突变型慢性淋巴细胞白血病细胞对奥法木单抗和利妥昔单抗的体外敏感性不同。
Exp Hematol. 2014 Oct;42(10):867-74.e1. doi: 10.1016/j.exphem.2014.06.003. Epub 2014 Jun 23.
9
Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion.
Leukemia. 2001 Jan;15(1):186-7. doi: 10.1038/sj.leu.2401987.
10
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.利妥昔单抗的一种IgG3转换变体对低CD20表达水平的肿瘤细胞介导增强的补体依赖性细胞毒性。
Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7.

引用本文的文献

1
Potassium/sodium cation carriers robustly up-regulate CD20 antigen by targeting MYC, and synergize with anti-CD20 immunotherapies to eliminate malignant B cells.钾/钠阳离子载体通过靶向MYC强力上调CD20抗原，并与抗CD20免疫疗法协同作用以消除恶性B细胞。
Haematologica. 2024 Dec 19. doi: 10.3324/haematol.2024.285826.
2
Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma.转录组特征分析揭示了索拉非尼耐药的肝细胞癌的预后分子特征。
Aging (Albany NY). 2021 Jan 20;13(3):3969-3993. doi: 10.18632/aging.202365.
3
How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application.

本文引用的文献

1
STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma.STAT3 靶点提示弥漫性大 B 细胞淋巴瘤侵袭性肿瘤发生的机制。
G3 (Bethesda). 2013 Dec 9;3(12):2173-85. doi: 10.1534/g3.113.007674.
2
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).索拉非尼（BAY 43-9006）治疗复发性弥漫性大 B 细胞淋巴瘤的 II 期研究：东部肿瘤协作组研究（E1404）。
J Hematol Oncol. 2013 Jul 5;6:46. doi: 10.1186/1756-8722-6-46.
3
Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy.
补体如何影响血液系统恶性肿瘤：从基础机制到临床应用。
Front Immunol. 2020 Oct 29;11:593610. doi: 10.3389/fimmu.2020.593610. eCollection 2020.
4
Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody.利妥昔单抗联合新型抗补体因子H抗体介导的B细胞慢性淋巴细胞白血病细胞的补体依赖性细胞毒性增强。
PLoS One. 2017 Jun 28;12(6):e0179841. doi: 10.1371/journal.pone.0179841. eCollection 2017.
慢性淋巴细胞白血病——发病机制和治疗中的微环境作用。
Br J Haematol. 2013 Jul;162(1):15-24. doi: 10.1111/bjh.12344. Epub 2013 Apr 25.
4
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.索拉非尼通过调节巨噬细胞和自然杀伤细胞之间的串扰来维持细胞抗癌效应功能。
Hepatology. 2013 Jun;57(6):2358-68. doi: 10.1002/hep.26328.
5
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.索拉非尼抑制自然杀伤细胞促进肝癌的促转移作用。
PLoS One. 2013;8(2):e55945. doi: 10.1371/journal.pone.0055945. Epub 2013 Feb 8.
6
Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy.奥法妥木单抗在裂解全血中的 B 慢性淋巴细胞白血病细胞方面比利妥昔单抗更有效，并且与化疗联合使用时也是如此。
J Immunol. 2013 Jan 1;190(1):231-9. doi: 10.4049/jimmunol.1202645. Epub 2012 Dec 5.
7
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.索拉非尼治疗复发或难治性淋巴瘤患者的 II 期研究。
Br J Haematol. 2012 Jul;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x. Epub 2012 May 10.
8
Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).索拉非尼诱导慢性淋巴细胞白血病细胞凋亡与 RAF 和髓样细胞白血病序列 1（Mcl-1）下调有关。
Mol Med. 2012 Feb 10;18(1):19-28. doi: 10.2119/molmed.2011.00164.
9
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.索拉非尼通过下调 Mcl-1 的翻译诱导慢性淋巴细胞白血病细胞死亡。
Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
10
STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells.STAT3 在丝氨酸 727 残基上持续磷酸化，与 DNA 结合，并在 CLL 细胞中激活转录。
Blood. 2010 Apr 8;115(14):2852-63. doi: 10.1182/blood-2009-10-230060. Epub 2010 Feb 12.